DURECT

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DURECT reports robust revenue growth and advances AHFIRM trial

DURECT's financials improved notably in 2022, driven by milestone payments and revenue growth.
AHFIRM trial progress and potential of larsucosterol offer promising prospects for the company.
Balancing high R&D costs, regulatory milestones, and market competition are key challenges.
Strategic management of cash reserves and successful trial outcomes are critical for future success.

DURECT (DRRX) advances promising AH treatment with strong Q1 results

DURECT's Q1 performance reflects progress in the development of Larsucosterol for AH.
Strengths lie in positive clinical data, regulatory support, and market awareness.
Challenges include market recall, pricing strategy, and potential dosing issues.
Opportunities exist in market expansion, regulatory milestones, and cost-saving potential.

DURECT reports Q2 revenue, progresses AHFIRM trial, eyes oncology expansion

DURECT's Q2 2023 performance reflects a balance between revenue generation, strategic investments, and financial strengthening.
The company's strengths lie in advancing clinical trials, exploring new markets, and planning for commercial success.
Challenges include regulatory hurdles, financial sustainability, and addressing analyst inquiries, while opportunities abound in oncology expansion and market growth.
Overall, DURECT's focus on innovation, strategic partnerships, and market awareness positions it for future success and growth.

DURECT reports positive trial results for larsucosterol in AH

DURECT's financials and cash position remain stable, with a successful net proceeds raise and operational funding secured.
Larsucosterol's positive trial results and FDA Fast Track designation position it as a promising treatment for AH.
While challenges exist in regulatory pathways and trial complexities, the market potential for larsucosterol is substantial.
Overall, DURECT's focus on addressing AH with an effective treatment underscores its commitment to patient care.

DURECT reports revenue decline but positive trial results for larsucosterol

DURECT saw a decline in revenues but managed to reduce R&D and SG&A expenses in 2023.
Positive trial results and feedback position larsucosterol as a promising therapy for alcohol-associated hepatitis.
Navigating revenue challenges, regulatory discussions, and cost management are key focus areas for DURECT.

DURECT reports Q1 revenue dip, eyes FDA approval for AH treatment

DURECT's Q1 2024 performance saw revenue decline but cost management improvements.
Progress in larsucosterol Phase III trial and AHFIRM data acceptance signal positive developments.
While revenue challenges persist, opportunities in AH treatment market and financial stability are notable.
Strategic focus on AH patients' needs and efficient trial design position DURECT for future success.

DURECT reports revenue growth and progress in life-saving therapy trials

DURECT's Q2 2024 performance showed revenue growth and significant expense reductions.
Strengths lie in breakthrough therapy designation, positive study results, and cost-efficient trial planning.
Challenges include managing cash burn, meeting trial timelines, and industry competition.
Opportunities exist in market expansion, partnerships, pipeline diversification, and cost optimization.

DURECT reports improved Q3 financials and progresses key clinical trials

DURECT's financials improved in Q3 2024 with lower expenses and stable revenues, while advancing key clinical trials.
Despite challenges like licensing agreement termination, the company is poised for growth with promising trial results and strategic opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DURECT's (DRRX) CEO Jim Brown on Q1 2021 Results - Earnings Call Transcript

Shares of Durect (NASDAQ:DRRX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% year over year to ($0.05), which missed the estimate of ($0.04).

Durect: Q1 Earnings Insights

CUPERTINO, Calif., May 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update.

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs

Atossa Genetics

China Rapid Finance

Reddit penny stocks to watch as May 2021 gets kicked off The post Best Penny Stocks To Buy In May 2021? Take A Look At These Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy In May 2021? Take A Look At These Right Now

CUPERTINO, Calif., April 27, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2021 financial results and host a conference call after the market close on Tuesday, May 4, 2021.

DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4

CUPERTINO, Calif., March 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed research paper describing the binding sites and proposed mechanism of action of its lead drug candidate, an endogenous sulfated oxysterol and epigenetic regulator, DUR-928, in The Journal of Lipid Research.

DURECT Corporation Announces Publication of DUR-928's Mechanism of Action

DURECT Corporation (DRRX) CEO Jim Brown on Q4 2020 Results - Earnings Call Transcript

Shares of Durect (NASDAQ:DRRX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 100.00% year over year to ($0.04), which missed the estimate of ($0.03).

Durect: Q4 Earnings Insights

CUPERTINO, Calif., March 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2020 and provided a corporate update. "We have achieved a number of important milestones over the past few months, most...

DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs

CUPERTINO, Calif., March 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in three upcoming investor conferences, taking place in March 2021. All conferences will take place virtually. Details are as follow: H.C. Wainwright Life Sciences...

DURECT Corporation to Participate in Three Investor Conferences in March 2021

Durect has been all over the place, but its AH indication is the one that looks like its best bet. Phase 2a data was very positive.

Durect: Positive Data In Alcoholic Hepatitis, But Catalysts Too Far Away

CUPERTINO, Calif., Feb. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its...

DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock

CUPERTINO, Calif., Feb. 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its...

DURECT Corporation Announces Proposed Offering of Common Stock

The FDA has granted approval to DURECT Corporation's (NASDAQ: DRRX) POSIMIR (bupivacaine solution), a non-opioid, sustained-release local analgesic for the treatment of post-surgical pain following arthroscopic subacromial decompression surgery (a type of shoulder surgery), for up to 72 hours.

DURECT Shares Soar After FDA Nod For Post-Surgical Pain Medication Posimir

Shares of Durect Corp. gained 34.3% in premarket trading on Tuesday after the company said its drug, Posimer, had been approved by the Food and Drug Administration as a treatment for pain after a certain type of shoulder surgery. The drug is not an opioid.

Durect stock soars 34% after it gets FDA approval for surgical pain treatment

CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) for infiltration use in adults for administration into the subacromial space under direct...

DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression

HarborOne Bancorp

International Seaways

Investors who target growth could be interested in the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.

3 Fast-Growing Small Caps to Consider

CUPERTINO, Calif., Jan. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020. About DURECT Corporation DURECT is a biopharmaceutical company...

DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million

CUPERTINO, Calif., Dec. 7, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has signed an agreement to sell its LACTEL Absorbable Polymer (LACTEL) product line to Evonik, a global leader in specialty chemicals. Under the terms of the agreement, Evonik will...

DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million

CUPERTINO, Calif., Nov. 13, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in nonalcoholic steatohepatitis (NASH) patients in a poster presentation at The AASLD Liver Meeting...

DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020

DURECT Corporation (DRRX) CEO Jim Brown on Q3 2020 Results - Earnings Call Transcript

Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -23.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q3 Loss, Lags Revenue Estimates

CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver diseases, today announced it has appointed Norman Sussman, M.D. as its Chief Medical Officer,...

DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer

CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, "Covid-19 Therapeutics in Development," taking place on Wednesday, October 28, 2020. The ROTH Healthcare and Biotechnology team...

DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development"

Durect (DRRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for DURECT Stock (DRRX)